---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-24-000105"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:04:02.340991+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics restates net loss per share from 2023-2024; material weakness in controls

## Summary
- Restating audited and unaudited financials from Dec 31, 2023 to Sep 30, 2024 due to misapplication of GAAP in EPS calculation for preferred stock.
- Common stock net loss per share changed for all affected periods; e.g., Q3 2024 revised from ($1.36) to ($1.06).
- Series A Preferred stock EPS restated (e.g., Q3 2024: ($42.22) vs. not previously reported).
- Material weakness in internal controls over financial reporting identified; remediation plan to be filed.
- No impact on cash position or other financial data; amendments to prior filings expected soon.

## SEC filing metadata
- accession: 0001636282-24-000105
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000105/0001636282-24-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000105/syre-20241118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-24-000105
- JSON: https://secwatch.observer/filing/0001636282-24-000105.json
- Plain text: https://secwatch.observer/filing/0001636282-24-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.